



APPENDIX

Supplementary Figure 1. Number of CUA guidelines published each year.



Supplementary Figure 2. Trends in overall authorship ($p=0.86$), first authorship ($p=0.45$), and last authorship ($p=0.02$) among all authors over time.



Supplementary Table 1. CUA report characteristics		
	n (%)	
Characteristic	All reports n=112	Reports without women authors n=43
Report type		
Guideline	70 (62.5)	34 (79.1)
Best practice report	13 (11.6)	6 (14.0)
Consensus statement	29 (25.9)	3 (7.0)
Topic		
Andrology/infertility/sexual health	11 (9.8)	9 (20.9)
Endourology	6 (5.4)	3 (7.0)
Functional urology	11 (9.8)	2 (4.7)
General urology	8 (7.1)	5 (11.6)
Pediatric urology	12 (10.7)	3 (7.0)
Urologic oncology	64 (57.1)	21 (48.8)
Year of publication		
2007–2012	26 (23.2)	14 (32.6)
2013–2018	38 (33.9)	19 (44.2)
2019–2024	48 (42.9)	10 (23.3)
Number of authors, median (IQR)	9 (5-15)	6 (4-10)

CUA: Canadian Urological Association; IQR: interquartile range.

Supplementary Table 2. Gender breakdown of CUA guideline authorship		
	n (%)	
Author category	All authors n=1172	Urologist authors n=750
Men first authors	93 (7.9)	82 (10.9)
Women first authors	24 (2.0)	17 (2.3)
Men middle authors	806 (68.8)	540 (72.0)
Women middle authors	144 (12.3)	36 (4.8)
Men last authors	91 (7.8)	72 (9.6)
Women last authors	14 (1.2)	3 (0.4)

CUA: Canadian Urological Association.

Supplementary Table 3. Characteristics of all authors overall and by gender				
Characteristic	n (%)			p
	All authors n=1172	Men n=990	Women n=182	
Author type				0.26
First	117 (10.0)	93 (9.4)	24 (13.2)	
Middle	950 (81.1)	806 (81.4)	144 (79.1)	
Last	105 (9.0)	91 (9.2)	14 (7.7)	
Physician	1115 (95.1)	972 (98.2)	143 (78.6)	<0.001
Specialty				<0.001
Urology	750 (64.0)	694 (70.1)	56 (30.8)	
Medical oncology	245 (20.9)	177 (17.9)	68 (37.4)	
Radiation oncology	67 (5.7)	60 (6.1)	7 (3.9)	
Pathology	12 (1.0)	9 (0.9)	3 (1.7)	
Radiology	12 (1.0)	10 (1.0)	2 (1.1)	
Other physician	29 (2.5)	22 (2.2)	7 (3.9)	
Medical non-physician	16 (1.4)	3 (0.3)	13 (7.1)	
PhD	14 (1.2)	2 (0.2)	12 (6.6)	
Patient	8 (0.7)	7 (0.7)	1 (0.6)	
Admin/research/student	19 (1.6)	6 (0.6)	13 (7.1)	
Province				<0.001
Alberta	118 (10.1)	109 (11.0)	9 (5.0)	
British Columbia	123 (10.5)	110 (11.1)	13 (7.1)	
Manitoba	34 (2.9)	26 (2.6)	8 (4.4)	
National	9 (0.8)	7 (0.7)	2 (1.1)	
New Brunswick	7 (0.6)	4 (0.4)	3 (1.7)	
Newfoundland and Labrador	5 (0.4)	4 (0.4)	1 (0.6)	
Nova Scotia	75 (6.4)	51 (5.2)	24 (13.2)	
Ontario	532 (45.4)	440 (44.4)	92 (50.6)	
Quebec	244 (20.8)	217 (21.9)	27 (14.8)	
Saskatchewan	7 (0.6)	6 (0.6)	1 (0.6)	
Outside Canada	18 (1.5)	16 (1.6)	2 (1.1)	
Guideline topic				<0.001
Andrology/infertility/sexual health	82 (7.0)	80 (8.1)	2 (1.1)	
Endourology	49 (4.2)	40 (4.0)	9 (5.0)	
Functional urology	74 (6.3)	48 (4.9)	26 (14.3)	
General urology	44 (3.8)	40 (4.0)	4 (2.2)	
Pediatric urology	39 (3.3)	21 (2.1)	18 (9.9)	
Urologic oncology	884 (75.4)	761 (76.9)	123 (67.6)	

Supplementary Table 4. Repeated authorship among all authors				
	n (%)			
Authorship frequency	Unique authors n=387	Unique men authors n=293	Unique women authors n=94	p
≥2	177 (45.7)	147 (50.2)	30 (31.9)	0.002
≥5	66 (17.1)	60 (20.5)	6 (6.4)	0.002
≥10	24 (6.2)	21 (7.2)	3 (3.2)	0.16

Supplementary Table 5. Updated CUA guidelines					
Topic	Version	Women authors / Total authors	Woman first author	Woman last author	Women authorship (%)
Management of castration-resistant prostate cancer	2010	0 / 2	N	N	0
	2013	0 / 13	N	N	0
	2015	0 / 14	N	N	0
	2019	1 / 16	N	N	6.3
	2021	1 / 16	N	N	6.3
	2022	1 / 16	N	N	6.3
Management of advanced kidney cancer	2013	4 / 22	N	Y	18.2
	2015	4 / 15	N	Y	26.7
	2017	3 / 23	N	N	13.0
	2019	4 / 22	N	N	18.2
	2021	4 / 22	Y	N	18.2
Bladder cancer quality of care	2016	1 / 27	N	N	3.7
	2018	1 / 26	N	N	3.8
	2020	3 / 37	N	N	8.1
Management of kidney cancer	2008	2 / 4	N	Y	50.0
	2009	2 / 5	N	Y	40.0
	2012	3 / 6	N	Y	50.0
Evaluation and management of azoospermia	2010	0 / 7	N	N	0
	2015	1 / 11	N	N	9.1
	2023	1 / 17	N	Y	5.9
Management of cystic renal lesions	2010	0 / 1	N	-	0
	2017	0 / 9	N	N	0
	2023	0 / 14	N	N	0
Male LUTS/BPH	2010	0 / 5	N	N	0
	2018	0 / 6	N	N	0
	2022	1 / 7	N	N	14.3
Evaluation and medical management of kidney stones	2010	0 / 4	N	N	0
	2016	3 / 7	Y	N	42.9
	2022	4 / 10	N	N	40

Singh et al. Gender differences in authorship of Canadian Urological Association guidelines

Prostate cancer screening	2011	1 / 8	N	Y	12.5
	2017	0 / 8	N	N	0
	2022	0 / 8	N	N	0
Vasectomy	2010	0 / 1	N	-	0
	2016	0 / 3	N	N	0
	2022	0 / 4	N	N	0
Sports and the solitary kidney	2009	1 / 1	Y	-	100
	2014	1 / 1	Y	-	100
	2019	4 / 5	Y	Y	80
Management of non-muscle invasive bladder cancer	2010	0 / 10	N	N	0
	2015	0 / 13	N	N	0
	2021	0 / 19	N	N	0
Adjuvant therapy for renal cell carcinoma	2018	3 / 26	N	N	11.5
	2023	4 / 24	N	N	16.7
Incidentally discovered adrenal mass	2011	0 / 3	N	N	0
	2023	1 / 10	N	N	10.0
Metastatic castration-naive and castration-sensitive prostate cancer	2020	2 / 12	N	N	16.7
	2022	2 / 13	N	N	15.4
Androgen deprivation therapy	2021	1 / 12	Y	N	8.3
	2022	1 / 12	Y	N	8.3
Management of testicular germ cell cancer	2010	6 / 21	Y	N	28.6
	2022	5 / 19	N	Y	26.3
Management of small renal masses	2015	0 / 16	N	N	0
	2022	2 / 21	N	N	9.5
Management of ureteral calculi	2015	0 / 6	N	N	0
	2021	2 / 13	N	N	15.4
Erectile dysfunction	2015	0 / 5	N	N	0
	2021	0 / 10	N	N	0
Antenatally detected hydronephrosis	2009	1 / 2	Y	N	50.0
	2018	0 / 3	N	N	0
Interstitial cystitis	2009	1 / 4	Y	N	25.0
	2016	4 / 7	Y	N	57.1
Multicystic dysplastic kidney in the neonate	2010	1 / 1	Y	-	100
	2016	1 / 1	Y	-	100
Follow-up of patients after treatment of non-metastatic renal cell carcinoma	2009	0 / 11	N	N	0
	2018	0 / 15	N	N	0

BPH: benign prostatic hyperplasia; CUA: Canadian Urological Association; LUTS: lower urinary tract symptoms.

Supplementary Table 6. Characteristics of all authors overall and by gender, excluding authors of consensus statements				
Characteristic	n (%)			p
	All authors n=687	Men n=591	Women n=96	
Author type				0.11
First	88 (12.8)	71 (12.0)	17 (17.7)	
Middle	523 (76.1)	450 (76.1)	73 (76.0)	
Last	76 (11.1)	70 (11.8)	6 (6.3)	
Physician	664 (96.7)	584 (98.8)	80 (83.3)	<0.001
Specialty				<0.001
Urology	550 (80.1)	497 (84.1)	53 (55.2)	
Medical oncology	47 (6.8)	32 (5.4)	15 (15.6)	
Radiation oncology	30 (4.4)	26 (4.4)	4 (4.2)	
Pathology	5 (0.7)	4 (0.7)	1 (1.0)	
Radiology	11 (1.6)	9 (1.5)	2 (2.1)	
Other physician	21 (3.1)	16 (2.7)	5 (5.2)	
Medical non-physician	5 (0.7)	0 (0)	5 (5.2)	
PhD	7 (1.0)	2 (0.3)	5 (5.2)	
Patient	0 (0)	0 (0)	0 (0)	
Admin/research/student	11 (1.6)	5 (0.9)	6 (6.3)	
Province				0.04
Alberta	57 (8.3)	51 (8.6)	6 (6.3)	
British Columbia	80 (11.6)	72 (12.2)	8 (8.3)	
Manitoba	18 (2.6)	10 (1.7)	8 (8.3)	
National	0 (0)	0 (0)	0 (0)	
New Brunswick	5 (0.7)	4 (0.7)	1 (1.0)	
Newfoundland and Labrador	4 (0.6)	4 (0.7)	0 (0)	
Nova Scotia	47 (6.8)	38 (6.4)	9 (9.4)	
Ontario	303 (44.1)	264 (44.7)	39 (40.6)	
Quebec	156 (22.7)	133 (22.5)	23 (24.0)	
Saskatchewan	7 (1.0)	6 (1.0)	1 (1.0)	
Outside Canada	10 (1.5)	9 (1.5)	1 (1.0)	
Guideline topic				<0.001
Andrology/infertility/sexual health	82 (11.9)	80 (13.5)	2 (2.1)	
Endourology	49 (7.1)	40 (6.8)	9 (9.4)	
Functional urology	74 (10.8)	48 (8.1)	26 (27.1)	
General urology	44 (6.4)	40 (6.8)	4 (4.2)	
Pediatric urology	39 (5.7)	21 (3.6)	18 (18.8)	
Urologic oncology	399 (58.1)	362 (61.3)	37 (38.5)	

Supplementary Table 7. Repeated authorship among all authors, excluding authors of consensus statements				
	n (%)			
Authorship frequency	Unique authors n=284	Unique men authors n=222	Unique women authors n=62	p
≥2	121 (42.6)	104 (46.9)	17 (27.4)	0.006
≥5	32 (11.3)	29 (13.1)	3 (4.8)	0.07
≥10	10 (3.5)	10 (4.5)	0 (0)	0.09

Supplementary Table 8. Characteristics of urologist authors overall and by gender, excluding authors of consensus statements				
	No. (%)			
Characteristic	Urologist authors n=550	Men urologists n=497	Women urologists n=53	p
Author type				0.004
First	84 (15.3)	68 (13.7)	16 (30.2)	
Middle	403 (73.3)	369 (74.3)	34 (64.2)	
Last	63 (11.5)	60 (12.1)	3 (5.7)	
Academic degree				0.08
MD	317 (57.6)	293 (59.0)	24 (45.3)	
MD + Master's	200 (36.4)	177 (35.6)	23 (43.4)	
MD + PhD	33 (6.0)	27 (5.4)	6 (11.3)	
Province				<0.001
Alberta	38 (6.9)	36 (7.2)	2 (3.8)	
British Columbia	61 (11.1)	55 (11.1)	6 (11.3)	
Manitoba	17 (3.1)	9 (1.8)	8 (15.1)	
New Brunswick	4 (0.7)	4 (0.8)	0 (0)	
Newfoundland and Labrador	4 (0.7)	4 (0.8)	0 (0)	
Nova Scotia	42 (7.6)	37 (7.4)	5 (9.4)	
Ontario	233 (42.4)	223 (44.9)	10 (18.9)	
Quebec	135 (24.6)	115 (23.1)	20 (37.7)	
Saskatchewan	7 (1.3)	6 (1.2)	1 (1.9)	
Outside Canada	9 (1.6)	8 (1.6)	1 (1.9)	
Guideline topic				<0.001
Andrology/infertility/sexual health	79 (14.4)	77 (15.5)	2 (3.8)	
Endourology	43 (7.8)	37 (7.4)	6 (11.3)	
Functional urology	67 (12.2)	45 (9.1)	22 (41.5)	
General urology	36 (6.6)	34 (6.8)	2 (3.8)	
Pediatric urology	37 (6.7)	20 (4.0)	17 (32.1)	
Urologic oncology	288 (52.4)	284 (57.1)	4 (7.6)	

Supplementary Table 9. Repeated authorship among urologist authors, excluding authors of consensus statements				
	n (%)			
Authorship frequency	Unique urologist authors n=193	Unique men urologist authors n=164	Unique women urologist authors n=29	p
≥2	104 (53.9)	91 (55.5)	13 (44.8)	0.29
≥5	26 (13.5)	24 (14.6)	2 (6.9)	0.26
≥10	10 (5.2)	10 (6.1)	0 (0)	0.17